Immunosuppressive treatment for autoimmune blistering diseases does not impair production of neutralizing antibodies after “booster” dose of <scp>COVID</scp>‐19 vaccine
Roberto Russo(Ospedale Policlinico San Martino), Aurora Parodi(Ospedale Policlinico San Martino), Emanuele Cozzani(Ospedale Policlinico San Martino), Giulia Gasparini(University of Genoa), Paola Canepa(Martin University), Niccolò Capurro(Ospedale Policlinico San Martino)
Cited by 0
Related Papers
European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes
|Journal of the European Academy of Dermatology and Venereology|2017|261
Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis
|British Journal of Dermatology|2006|136
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)
|Frontiers in Medicine|2023|55
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study
|Expert Opinion on Biological Therapy|2020|43
Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)
|Dermatology Practical & Conceptual|2024|34